Non Invasive Brain Stimulation Unit/Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.
Non Invasive Brain Stimulation Unit/Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy; Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Brain Stimul. 2020 Sep-Oct;13(5):1175-1182. doi: 10.1016/j.brs.2020.05.013. Epub 2020 May 30.
New diagnostic criteria consider Alzheimer's disease (AD) as a clinico-biological entity identifiable in vivo on the presence of specific patterns of CSF biomarkers.
Here we used transcranial magnetic stimulation to investigate the mechanisms of cortical plasticity and sensory-motor integration in patients with hippocampal-type memory impairment admitted for the first time in the memory clinic stratified according to CSF biomarkers profile.
Seventy-three patients were recruited and divided in three groups according to the new diagnostic criteria: 1) Mild Cognitive Impaired (MCI) patients (n = 21); Prodromal AD (PROAD) patients (n = 24); AD with manifest dementia (ADD) patients (n = 28). At time of recruitment all patients underwent CSF sampling for diagnostic purposes. Repetitive and paired-pulse transcranial magnetic stimulation protocols were performed to investigate LTP-like and LTD-like cortical plasticity, short intracortical inhibition (SICI) and short afferent inhibition (SAI). Patients were the followed up during three years to monitor the clinical progression or the conversion to dementia.
MCI patients showed a moderate but significant impairment of LTP-like cortical plasticity, while ADD and PROAD groups showed a more severe loss of LTP-like cortical plasticity. No differences were observed for LTD-like cortical plasticity, SICI and SAI protocols. Kaplan-Meyer analyses showed that PROAD and MCI patients converting to dementia had weaker LTP-like plasticity at time of first evaluation.
LTP-like cortical plasticity could be a novel biomarker to predict the clinical progression to dementia in patients with memory impairment at prodromal stages of AD identifiable with the new diagnostic criteria based on CSF biomarkers.
新的诊断标准将阿尔茨海默病(AD)视为一种可以在体内通过特定的脑脊液生物标志物模式识别的临床生物学实体。
本研究使用经颅磁刺激来研究海马型记忆障碍患者的皮质可塑性和感觉运动整合的机制,这些患者首次因记忆障碍到记忆门诊就诊,并根据脑脊液生物标志物图谱进行分层。
共招募了 73 名患者,并根据新的诊断标准分为三组:1)轻度认知障碍(MCI)患者(n=21);2)前驱 AD(PROAD)患者(n=24);3)有明显痴呆的 AD(ADD)患者(n=28)。在招募时,所有患者均进行了脑脊液取样以进行诊断。进行重复和成对脉冲经颅磁刺激方案,以研究长时程增强(LTP)样和 LTD 样皮质可塑性、短程抑制(SICI)和短程传入抑制(SAI)。对患者进行了三年的随访,以监测临床进展或向痴呆的转化。
MCI 患者表现出中等但显著的 LTP 样皮质可塑性损伤,而 ADD 和 PROAD 组表现出更严重的 LTP 样皮质可塑性损伤。LTD 样皮质可塑性、SICI 和 SAI 方案没有差异。Kaplan-Meier 分析显示,PROAD 和 MCI 患者在首次评估时向痴呆转化的患者,其 LTP 样可塑性较弱。
LTP 样皮质可塑性可能是一种新的生物标志物,可预测具有基于脑脊液生物标志物的新诊断标准的 AD 前驱期记忆障碍患者向痴呆的临床进展。